Listed by the USPTO as BARSKY, JARED
Tech Center 1600 • Art Units: 1626 1628 1629
This examiner grants 50% of resolved cases
BARSKY, JARED is assigned to Tech Center 1600 and Art Unit 1626. The record covers 947 resolved cases, with a 50.3% allowance rate and a 22.8% interview lift. The interview result supports direct engagement as one option for addressing prosecution barriers.
The median time to allowance is 950 days. The leading companies are Boehringer Ingelheim International GmbH, DSM IP Assets B.V., and AltaThera Pharmaceuticals LLC. The listed firms are COOLEY LLP, Milstein Zhang & Wu LLC, and NEW RIVER VALLEY INTELLECTUAL.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18493126 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | Final Rejection | Boehringer Ingelheim International GmbH |
| 18362034 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | Final Rejection | Boehringer Ingelheim International GmbH |
| 18832236 | NOVEL REGIMEN FOR AUGMENTING AND EXTENDING TRANSPLANT TOLERANCE | Non-Final OA | The Regents of the University of California |
| 18866387 | COMPOSITIONS AND METHODS USING A COMBINATION OF FISETIN AND QUERCETIN FOR CELLULAR ENERGY | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18555104 | RETINOL FORMULATION (I) | Final Rejection | DSM IP ASSETS B.V. |
| 17397911 | AMELIORATING AGENT FOR FEMALE-SPECIFIC PHYSICAL AND/OR MENTAL UNPLEASANT SYMPTOM | Final Rejection | OTSUKA PHARMACEUTICAL CO., LTD. |
| 17910613 | METABOLITES RELEASED FROM APOPTOTIC CELLS ACT AS NOVEL TISSUE MESSENGERS | Final Rejection | University of Virginia Patent Foundation |
| 18689758 | Improvement of Tumor Immunogenicity by Means of Splicing-Controlling Compound | Non-Final OA | Kyoto University |
| 18553858 | METHOD FOR CONTROLLING DISEASE-TRANSMITTING INSECTS USING CONDENSED HETEROCYCLIC COMPOUND | Final Rejection | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 14903114 | DRUG FOR TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE | Non-Final OA | KOWA COMPANY, LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy50.3% of resolved applications examined by Jared Barsky were allowed (947 resolved cases), compared with 54.9% across Art Unit 1626 over the last five years.
This examiner's interview lift is +22.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Jared Barsky took 950 days on average from filing to allowance.
Jared Barsky examines applications in Art Unit 1626 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
